Tumor mutational burden assessed by a targeted NGS assay predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer
Title:
Tumor mutational burden assessed by a targeted NGS assay predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer
Author:
Jermann, P. Alborelli, I. Leonards, K. Rothschild, S.I. Leuenberger, L. Savic Prince, S. Mertz, K. Poechtrager, S. Zippelius, A. Quagliata, L. Bubendorf, L.